0.00Open0.15Pre Close0 Volume1 Open Interest75.00Strike Price0.00Turnover334.41%IV67.98%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type-0.0038Delta0.0001Gamma1558.27Leverage Ratio-0.0729Theta-0.0002Rho-5.99Eff Leverage0.0037Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet